Synonym
Biotirmone; Debetrol; Dethyrona; Detyroxin; Dextroid; Dextroxin; Choloxin; D-Thyroxine; D-T4 Thyroid Hormon; D-Thyroxine; Dextrothyroxine; Dextrothyroxine
IUPAC/Chemical Name
(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
InChi Key
XUIIKFGFIJCVMT-GFCCVEGCSA-N
InChi Code
InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m1/s1
SMILES Code
O=C(O)[C@H](N)CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1
Purity
>97% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
776.87
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: ZINN WJ, SCHLEISSNER LA. THE EFFECTS OF DEXTROTHYROXINE IN DIABETES. Calif Med. 1964 Oct;101(4):240-5. PMID: 14204552; PMCID: PMC1515644.
2: Gage D, Bernard RD. Dextrothyroxine. N Y State J Med. 1972 Jun 15;72(12):1559. PMID: 4504212.
3: OWEN WR, OWENS JC, NEELY WB. Objective effects of dextrothyroxine therapy. Angiology. 1962 Feb;13:75-8. doi: 10.1177/000331976201300204. PMID: 14482905.
4: Gorman CA, Jiang NS, Ellefson RD, Elveback LR. Comparative effectiveness of dextrothyroxine and levothyroxine in correcting hypothyroidism and lowering blood lipid levels in hypothyroid patients. J Clin Endocrinol Metab. 1979 Jul;49(1):1-7. doi: 10.1210/jcem-49-1-1. PMID: 447807.
5: Calay R, Kocheleff P, Jonniaux G, Sohet L, Bastenie PA. Dextrothyroxine therapy for the disordered lipid metabolism of preclinical hypothyroidism. Lancet. 1971 Jan 30;1(7692):205-6. doi: 10.1016/s0140-6736(71)90948-2. PMID: 4099873.
6: Bechtol LD, Warner WL. Dextrothyroxine for lowering serum cholesterol. Analysis of data on 6066 patients. Angiology. 1969 Nov;20(10):565-79. doi: 10.1177/000331976902001001. PMID: 5347944.
7: OWENS JC, NEELY WB, OWEN WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. Clin Med (Northfield). 1962 Oct;69:2283-4. PMID: 15445906.
8: Nandan R, Fisher JD, Towery EP, Brown DR, Ganote E, Jennings RB. Effects of dextrothyroxine on hyperlipidemia and experimental atherosclerosis in beagle dogs. Atherosclerosis. 1975 Sep-Oct;22(2):299-311. doi: 10.1016/0021-9150(75)90011-8. PMID: 172095.
9: STARR P. Sodium dextrothyroxine and sodium levothyroxine. Results of their use in an athyreotic patient with angina pectoris and hypercholesteremia. JAMA. 1960 Aug 27;173:1934-5. doi: 10.1001/jama.1960.73020350012016b. PMID: 13833863.
10: Evaluation of a hypocholesterolemic agent. Dextrothyroxine sodium (Choloxin). JAMA. 1969 May 12;208(6):1014-5. doi: 10.1001/jama.1969.03160060084012. PMID: 5818672.
11: Brun LD, Gagné C, Coulombe P, Lupien PJ, Dussault JH, Moorjani S. Effects of dextrothyroxine on the pituitary-thyroid axis in hypercholesterolemic children and goitrous adults. J Clin Endocrinol Metab. 1980 Dec;51(6):1306-10. doi: 10.1210/jcem-51-6-1306. PMID: 6777394.
12: Schwartz ID, Bercu BB. Dextrothyroxine in the treatment of generalized thyroid hormone resistance in a boy homozygous for a defect in the T3 receptor. Thyroid. 1992 Spring;2(1):15-9. doi: 10.1089/thy.1992.2.15. PMID: 1525565.
13: Best MM, Duncan CH. Effects of clofibrate and dextrothyroxine singly and in combination on serum lipids. Arch Intern Med. 1966 Aug;118(2):97-102. PMID: 5329616.
14: Dextrothyroxine for lowering cholesterol. Med Lett Drugs Ther. 1976 Jun 18;18(13):53. PMID: 934018.
15: Kritchevsky D. Arterial cholesterol esterase. Adv Exp Med Biol. 1977;82:878-81. doi: 10.1007/978-1-4613-4220-5_173. PMID: 920445.
16: Parker F. Xanthomas and hyperlipidemias. J Am Acad Dermatol. 1985 Jul;13(1):1-30. doi: 10.1016/s0190-9622(85)70139-9. PMID: 4031142.
17: Lees RS, Wilson DE. The treatment of hyperlipidemia. N Engl J Med. 1971 Jan 28;284(4):186-95. doi: 10.1056/NEJM197101282840406. PMID: 4923684.
18: Lewis B. Classification of hyperlipidaemias. Proc R Soc Med. 1971 Sep;64(9):905-8. PMID: 5114287; PMCID: PMC1812854.
19: FLOCK EV, DAVID C, HALLENBECK GA, OWEN CA Jr. METABOLISM OF D-THYROXINE. Endocrinology. 1963 Dec;73:764-74. doi: 10.1210/endo-73-6-764. PMID: 14089635.
20: WINKELMANN RK, KIERLAND RR, PERRY HO, MULLER SA. TREATMENT OF SCLERODERMA WITH SODIUM DEXTROTHYROXINE. Arch Dermatol. 1965 Jan;91:66-9. doi: 10.1001/archderm.1965.01600070072012. PMID: 14229604.
